Multiple sclerosis cost-effectiveness of therapy

Multiple sclerosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple sclerosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography or Ultrasound
CT Scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Alternative Therapies
Primary Prevention
Secondary Prevention
Tertiary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Multiple sclerosis cost-effectiveness of therapy On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Multiple sclerosis cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Multiple sclerosis cost-effectiveness of therapy
CDC on Multiple sclerosis cost-effectiveness of therapy
Multiple sclerosis cost-effectiveness of therapy in the news
Blogs on Multiple sclerosis cost-effectiveness of therapy
Directions to Hospitals Treating Multiple sclerosis
Risk calculators and risk factors for Multiple sclerosis cost-effectiveness of therapy

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Cost effectiveness

Given the morbidity and mortality associated with multiple sclerosis and the high cost of treating the acute attacks and disability of MS disease, treatment with IFN β-1a SC injection, IFNβ-1b SC injection, and glatiramer acetate is relatively cost-effective.